Serum Biomarker Status with a Distinctive Pattern in Prognosis of Gastroenteropancreatic Neuroendocrine Carcinoma.

Abstract

OBJECTIVE:

Gastroenteropancreatic neuroendocrine carcinoma (GEPNEC) is a major research focus, but the application of biomarkers to guide its prognostication and management is unsatisfying. Clinical values of conventional serum biomarkers, neuron-specific enolase (NSE), carcinoembryonic antigen (CEA), and carbohydrate antigen 19-9 (CA199) warrant scrutiny.

METHODS:

Patients diagnosed with GEPNEC with baseline NSE, CEA, and CA199 levels provided in Peking University Cancer Hospital were retrospectively studied. Relationships between biomarkers and prognosis were investigated by the χ2 test, Kaplan-Meier analysis, and univariate and multivariate Cox regression analyses.

RESULTS:

A total of 640 GEPNEC patients were enrolled. NSE, CEA, and CA199 were elevated in 59.5%, 28.5%, and 21.3% of the population, respectively. Higher NSE had worse median overall survival (OS) (17.0 months vs. not reached, hazard ratio = 2.77 [2.06, 3.73], p < 0.001), and so did patients with higher CEA and CA199. Multivariable analysis confirmed that NSE and CA199 correlated with OS independently. Baseline NSE level and NSE remission predicted OS and the response of patients with first-line etoposide plus cisplatin (EP) treatment. Furthermore, we combined NSE/CEA/CA199 to segregate GEPNEC into novel subgroups, namely, adenocarcinoma-like NEC (ALN), neuroendocrine-like NEC (NLN), and triple-normal NEC (TNN). The groups shared distinctive clinicopathologic features and prognosis (21.0 months vs. 17.1 months vs. not reached, p < 0.001). The EP regimen remained the priority treatment option in NLN/TNN, while ALN was predisposed to "adenocarcinoma-like chemotherapy."

CONCLUSIONS:

Elevation of NSE, CEA, or CA199 was common and independently indicates poor prognosis in GEPNEC patients. Serum biomarker-based subtypes suggest meaningful clinical implications and appropriate therapeutic approaches, illuminating promising ways to characterize the prognosis of GEPNEC.

• Authors: Jianwei Zhang, Yanshuo Cao, Panpan Zhang, Xiaotian Zhang, Jian Li, Jun Zhou, Xicheng Wang, Zhi Peng, Yu Sun, Jie Li, Lin Shen, Ming Lu
• Journal: Neuroendocrinology (Neuroendocrinology) Vol. 112 Issue 8 Pg. 733-743 ( 2022) ISSN: 1423-0194 [Electronic] Switzerland
• PMID: 34592743 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2021 The Author(s). Published by S. Karger AG, Basel.

Chemical References

• Biomarkers, Tumor
• Carcinoembryonic Antigen

Topics

• Adenocarcinoma (diagnosis)
• Biomarkers, Tumor (blood)
• Carcinoembryonic Antigen (blood)
• Carcinoma, Neuroendocrine (diagnosis)
• Humans
• Pancreatic Neoplasms (diagnosis)
• Prognosis
• Retrospective Studies